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Abstract
Background Older people are more sensitive to drugs and
adverse drug reactions than younger people because of age-
related physiological changes such as impaired renal
function. As people with dementia are particularly vul-
nerable to the effects of drugs, it is especially important to
evaluate the dosages of renally cleared medications in this
group.
Objective The aim of this study was to estimate the
prevalence of impaired renal function and inappropriate
prescriptions on the basis of renal function among older
patients with dementia or cognitive impairment.
Methods The medical records of 428 patients aged
C65 years who were admitted to two hospitals in northern
Sweden were reviewed and renally cleared medications
were identified. The Cockcroft–Gault equation was used to
evaluate renal function. Doses were evaluated according to
the Geriatric Dosage Handbook.
Results Renal function was impaired (estimated glomeru-
lar filtration rate \60 ml/min) in 65.4 % of the study
population. Impaired renal function was associated with
increasing age. Among 547 prescriptions identified as
renally cleared medications, 9.1 % were inappropriate
based on the patient’s renal function; 13.5 % of the 326
patients prescribed renally cleared medications had
inappropriate prescriptions. Inappropriate prescriptions
were more common among patients living in nursing
homes.
Conclusions Impaired renal function is common and
inappropriate prescription is prevalent among old people
with cognitive impairment in northern Sweden. Continuous
consideration of renal function is important when pre-
scribing medications to this group.
Key Points
Prescriptions classed as inappropriate on the basis of
impaired renal function is prevalent among older
people with cognitive impairment and dementia.
Impaired renal function is common among older
people with cognitive impairment and dementia.
Continuous estimation of renal function is important
in this group.
1 Introduction
Ageing populations are characterised by an increased
proportion of older people [1, 2]. In older populations,
chronic diseases, including dementia and mild cognitive
impairment, and comorbidity are common [2, 3].
Polypharmacy is common among older people with mul-
tiple chronic conditions. This situation is of particular
concern as older people are more sensitive to drugs and
adverse drug reactions (ADRs) than younger individuals
[2, 4]. The changes in neurotransmitter substances that
Electronic supplementary material The online version of this
article (doi:10.1007/s40266-016-0408-8) contains supplementary
material, which is available to authorized users.
& Maria Gustafsson
maria.gustafsson@umu.se
1 Department of Pharmacology and Clinical Neuroscience,
Umea˚ University, 901 87 Umea˚, Sweden
Drugs Aging (2016) 33:889–899
DOI 10.1007/s40266-016-0408-8
occur in people with dementia make this patient group
especially vulnerable to the effects of drugs, including
ADRs [1, 2, 5].
Age-related physiological changes affect the pharma-
cokinetic parameters of a drug, and the elimination of
drugs is particularly affected by impairment of renal
function [1, 2]. Renal mass declines with age as do the
number and size of nephrons [6], and this process results in
reduced glomerular and tubular filtration [2]. Chronic
kidney disease (CKD), defined as estimated glomerular
filtration rate (eGFR)\60 ml/min, is a common and
growing problem in older populations [6–8]. Renally
excreted drugs with narrow therapeutic indices, such as
digoxin and lithium, can accumulate and concentrations
can become toxic [9]. Drugs such as morphine and
glibenclamide that have active metabolites may cause
ADRs [10, 11]. Estimation of renal function is thus
important when prescribing renally excreted drugs to older
people to avoid inappropriate prescribing, which is defined
as ‘‘a situation where risk from the adverse effects of a
prescribed medication outweighs the desired clinical ben-
efits of treating a particular condition’’ [4].
eGFR is increasingly used in healthcare to estimate
patients’ renal function. The use of serum creatinine level
alone as a measure of renal function is not reliable [12]
because creatinine production, which is dependent on
muscle mass, decreases with age; thus, the use of serum
creatinine level alone leads to overestimation of renal
function [1, 6]. Two commonly used methods for calcu-
lating eGFR on the basis of serum creatinine level are the
Cockcroft–Gault (CG) equation and the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
[2, 13]. The CG equation calculates the absolute eGFR (ml/
min) [14]. Most recommendations published in dosage
handbooks are based on renal function estimated by the CG
equation [2, 6]. The CKD-EPI equation calculates the rel-
ative eGFR (ml/min/1.73 m2) and is used to detect and
characterise CKD [13–15]. Estimates of renal function
obtained via creatinine-based equations are less accurate in
certain patients such as those who are malnourished,
amputees and the morbidly obese [2, 12]. Debate con-
cerning the most suitable equation for calculating eGFR is
ongoing [6, 13, 16, 17].
As people with dementia are particularly vulnerable to
drugs, evaluation of whether medications need to be
adjusted according to renal function is especially important
in this group [5]. Several studies have evaluated older
people’s prescriptions in relation to their renal function
[4, 6, 8, 16, 18–22]. To our knowledge, no similar study
has been conducted among people with dementia or cog-
nitive impairment.
The purpose of this study was to estimate the prevalence
of impaired renal function and inappropriate prescription of
renally cleared medications among older people, aged
C65 years, with dementia or cognitive impairment. Factors
associated with impaired renal function and inappropriate
prescription were also investigated.
2 Methods
2.1 Setting and Study Design
This cross-sectional study used data collected in a ran-
domised controlled intervention study conducted in two
hospitals in northern Sweden. The purpose of the inter-
vention was to investigate whether drug-related readmis-
sions were reduced when clinical pharmacists conducted
medication reviews as part of ward teams. Patients
admitted to the acute internal medicine or orthopaedic ward
at Norrland University Hospital and to a medical ward at
the county hospital in Skelleftea˚ were recruited between 9
January 2012 and 2 December 2014. All admissions were
emergencies, except for one that was elective. The most
common reasons for admission were fractures/falls, heart
failure or pneumonia. A total of 460 people were ran-
domised to the intervention and control groups. Eligible
patients were those aged C65 years who had dementia or
cognitive impairment. Dementia diagnoses were collected
from medical records. Patients were considered to have
cognitive impairment if sufficient information related to
memory, orientation or executive function was noted in
their medical records prior to the index hospitalization. In
addition, patients in whom dementia was suspected and
medical investigation had been or would be commenced
were included. Ambiguous or uncertain cases were exclu-
ded. The procedure described was chosen to avoid the risk
of including people without dementia who had developed a
delirious or confused state during the hospital stay
(Gustafsson M et al., 2016, unpublished observations).
Each patient in the intervention group received an addi-
tional medication review by a clinical pharmacist, while
the control group received standard care.
Data for the present study were gathered from the
intervention study, with the patients assigned to the inter-
vention and control groups treated as a single study sample.
The study population comprised 460 people with dementia
or cognitive impairment. People who died (n = 31) or
withdrew from the intervention study (n = 1) before dis-
charge from the index hospitalization were excluded,
resulting in a final sample of 428 people.
2.2 Data Extraction
Data about the patients’ medications were extracted from
the medical records at the time of the patients’ index
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hospitalization, before any medication review was per-
formed. The Geriatric Dosage Handbook (GDH) was used
to identify renally cleared medications from among all
prescribed drugs to obtain internationally applicable results
[23]. Doses, strengths and drug formulations were noted for
every drug at the individual patient level. Pro re nata
medications, over-the-counter medications and formula-
tions designed for local administration were not included in
the analysis.
The GDH guidelines were used to evaluate whether
prescriptions were inappropriate relative to patients’ renal
function [23]. Another guideline was used for morphine
prescriptions as the GDH guideline was considered unclear
for this specific drug [10]. Moreover, mirabegron pre-
scriptions were evaluated according to another guideline
because the GDH did not include guidelines regarding this
drug [24]. Angiotensin-converting enzyme inhibitors were
excluded because of the large pharmacodynamic variations
and because these drugs are monitored after clinical
response [25]. Digoxin and dalteparin were excluded, as
consideration of serum concentrations and therapeutic
responses to these drugs is important [23, 26]. Inappro-
priate prescriptions were classified as representing exces-
sive doses (more than the maximum daily dosage) or
contraindications for patients with renal impairment
according to previous research [4, 6, 19]. Prescriptions not
requiring dosage adjustment were classified as having
appropriate doses relative to renal function.
The classification system shown in Table 1 was used to
define CKD stages. Renal function was considered to be
impaired in stages 3–5 (i.e. eGFR\ 60 ml/min[/1.73 m2]).
The CG equation, shown in Table S1 of the Electronic
Supplementary Material (ESM), was used to calculate the
eGFR (eGFRCG) to estimate the prevalence of impaired
renal function and inappropriate prescription. To compare
the frequencies of patients at different CKD stages using
different estimation methods, the relative eGFR was
calculated using the CKD-EPI equation, and the absolute
eGFR was calculated from the relative eGFR values
(equations shown in ESM Table S1).
The values required to calculate eGFR were extracted
from patients’ medical records. Data were collected on the
date of randomisation, which was usually within 2 days
(maximum 22 days) of admission date. We recorded
patients’ age, sex, serum creatinine level, weight (actual)
and height as well as the type of dementia, classified as
Alzheimer’s disease, vascular dementia or other or
unspecified (UNS) dementia. When available, Mini-Mental
State Examination (MMSE) scores were recorded.
Patients’ living situations were classified as living at home
or in a nursing home.
2.3 Data Analysis
Descriptive statistics were used to summarise the data.
Frequencies and proportions were calculated for dichoto-
mous variables, and continuous variables are presented as
mean values with standard deviations.
Simple logistic regression analyses were conducted to
investigate the association between impaired renal function
and factors extracted from the medical record: age, sex,
living situation and MMSE score. A multiple logistic
regression analysis was conducted including all variables
from the simple models except MMSE score because of the
large proportion of missing values and the absence of any
differences found on univariate analysis.
Further, simple logistic regression analyses were con-
ducted to investigate the association between inappropriate
prescription and factors extracted from the medical record
(age, sex, living situation and MMSE score). A multiple
logistic regression analysis was conducted including all
variables from the simple models except MMSE score
because of a large proportion of missing values and the
absence of any differences found on univariate analysis.
Results are presented as odds ratios (ORs) with 95 %
confidence intervals (CIs). All analyses were conducted
using IBM SPSS Statistics 22 (Somers, NY, USA).
3 Results
Of the 428 people included in the study, 270 (63.1 %) were
women; the mean age was 83.2 ± 6.6 years. The
mean ± standard deviation (SD) serum creatinine level
was 89.0 ± 39.7 lmol/l. The mean eGFR, calculated using
the CG equation, was 55.3 ± 22.6 ml/min. The absolute
and relative eGFRs using the CKD-EPI equation were
64.8 ± 22.0 ml/min and 64.6 ± 21.1 ml/min/1.73 m2,
respectively. The most common type of cognitive impair-
ment was other or UNS dementia (n = 225 [52.6 %]), and
Table 1 Classification of the different stages of chronic kidney dis-
ease based on glomerular filtration rate [1]
Stage Physiologic change GFR
(ml/min/1.73 m2)
– At increased risk for CKD C90 with risk
factors
1 CKD with normal or increased kidney
function
C90
2 CKD with mild impairment of kidney
function
60–89
3 Moderate impairment of kidney function 30–59
4 Severe impairment of kidney function 15–29
5 Terminal renal failure \15
CKD chronic kidney disease, GFR glomerular filtration rate
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the majority of patients (n = 304 [71.0 %]) lived at home
(Table 2).
The distribution of the five CKD stages in the study
sample is presented in Table 3. According to the absolute
eGFR calculated using the CKD-EPI equation, 173
(41.0 %) patients were estimated to have CKD stages 3–5
(i.e. eGFR\ 60 ml/min). Calculation of the relative eGFR
indicated that 173 (40.4 %) patients had eGFRs\ 60 ml/
min/1.73 m2. According to the CG equation, 280 (65.4 %)
patients were estimated to have impaired renal function
(i.e. eGFR\ 60 ml/min). Impaired renal function was
more common among women (OR 2.046 [95 % CI
1.358–3.082]) and in older patients (OR 1.204 [95 % CI
1.154–1.256]). There were no significant differences
between people with and without impaired renal function
in relation to living situation or MMSE score. In a multi-
variable model in which impaired renal function was the
dependent variable and sex, age and living situation were
independent variables, age remained significant (OR 1.203
[95 % CI 1.152–1.257]) (Table 4).
Of the drugs prescribed to the 428 patients, 58 were
classified as renally cleared medications; 547 prescriptions
of these 58 drugs were recorded (Table 5). Of these 547
prescriptions, 50 (9.1 %) were classified as inappropriate
and 497 prescriptions (90.9 %) were considered appropri-
ate on the basis of the patient’s renal function. When
absolute and relative eGFR were calculated according to
the CKD-EPI equation, the corresponding prevalences of
inappropriate prescriptions were 28 (5.1 %) and 32
(5.9 %), respectively. Inappropriate prescriptions were
found for 20 (34.5 %) of the 58 identified drugs. Of the 50
inappropriate prescriptions, 17 were for doses that were too
high and 33 were for contraindicated drugs; these consti-
tuted 3.1 % (17/547) and 6.0 % (33/547), respectively, of
all identified prescriptions. Eight (47.1 %) prescriptions
with excessive doses were for allopurinol and 12 (36.4 %)
contraindicated prescriptions were for metformin
(Table 5).
The majority (326/428 [76.2 %]) of patients in the study
sample were prescribed one or more renally cleared med-
ications. Of these 326 patients, 44 (13.5 %) had inappro-
priate prescriptions on the basis of their renal function;
these patients constituted 10.3 % of the total study sample.
Among the 326 patients prescribed one or more of the
identified medications, 15 (4.6 %) had one or more pre-
scriptions with excessive doses and 31 (9.5 %) had one or
more contraindicated prescription.
Inappropriate prescriptions were more common among
people living in nursing homes (OR 2.060 [95 % CI
1.073–3.954]). No significant difference was seen between
people with and without inappropriate prescriptions in
terms of sex, age or MMSE score. Nor were any significant
associations seen in a multivariable model in which inap-
propriate prescriptions was the dependent variable and sex,
age and living situation were independent variables
(Table 6).
Table 2 Descriptive statistics of the study sample
Characteristics of study sample
Cases (n) 428
Women 270 (63.1)
Age (years) 83.2 ± 6.6 (65–99)
Weight (kg) 68.2 ± 15.4 (32.8–130.0)
BMIa (kg/m2) 25.1 ± 4.9 (13.3–46.6)
Number of medications at admission 7.8 ± 3.5 (0–20)
Renal function
Cs,cr (lmol/L) 89.0 ± 39.7 (28.0–311.0)
eGFRCG (ml/min) 55.3 ± 22.6 (12.8–144.3)
eGFRCKD-EPI
a (ml/min) 64.8 ± 22.0 (11.3–126.2)
eGFRCKD-EPI (ml/min/1.73 m
2) 64.6 ± 21.1 (11.8–115.2)
MMSEb (0–30) 19.8 ± 4.6 (7–29)
Type of dementia
Alzheimer’s disease 131 (30.6)
Vascular dementia 72 (16.8)
Other or UNS dementia 225 (52.6)
Living situation
Living at home 304 (71.0)
Nursing home 124 (29.0)
Data are presented as frequencies, n (%) or mean ± standard devia-
tion (range) unless otherwise indicated
BMI body mass index, Cs,cr serum creatinine concentration, eGFRCG
estimated glomerular filtration rate using the Cockcroft–Gault equa-
tion, eGFRCKD-EPI estimated GFR using Chronic Kidney Disease
Epidemiology Collaboration equation, MMSE Mini-Mental State
Examination, UNS unspecified
a n = 422 due to lack of height data when calculating the BMI and
absolute eGFR
b n = 155 because the test was not performed in every patient
Table 3 Frequency of patients at different chronic kidney disease
stages using the CKD-EPI equation as the renal function estimation
method
CKD stage CKD-EPIa CKD-EPIb
1 56 (13.3) 42 (9.8)
2 193 (45.7) 213 (49.8)
3 148 (35.1) 149 (34.8)
4 23 (5.5) 23 (5.4)
5 2 (0.5) 1 (0.2)
Total 422 (98.6) 428 (100)
Data are presented as n (%)
CKD Chronic Kidney Disease, CKD-EPI Chronic Kidney Disease
Epidemiology Collaboration equation
a Absolute value (ml/min)
b Relative value (ml/min/1.73 m2)
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4 Discussion
In the present study, nearly two-thirds of patients had
impaired renal function, which was associated with
advancing age. Close to 10 % of the identified prescrip-
tions were inappropriate, affecting more than 10 % of
patients. The drugs most commonly involved were met-
formin, representing the majority of the contraindicated
prescriptions, and allopurinol, representing the majority of
the prescriptions with excessive doses.
According to values calculated using the CG equation,
the prevalence of impaired renal function was high in the
present study. The reported prevalence of impaired renal
function among older people ranges from 12 to 66 %
[15, 17, 27]. The wide variation in this parameter may be
due to differences in study setting, individual parameters
and the estimation equations used. The association between
impaired renal function and advancing age found in the
present study was expected and has been reported in sev-
eral other studies [8, 19, 28, 29]. The rate of decline in
renal function has been found to be greater in people with
concomitant diseases; diabetes, for example, is one of the
most common diseases associated with impaired renal
function [30, 31]. In this study, no significant difference
was seen between people with and without impaired renal
function regarding degree of cognitive impairment. A
similar result was seen in another study [27], which found
no association between CKD and cognitive decline or the
incidence of all-cause dementia. As the prevalence of
impaired renal function in this group was high, and as
impairment is often under-recognised among older people,
routine monitoring to detect deteriorating renal function is
important to avoid the consequences of inappropriate pre-
scriptions [8].
In the present study, close to 10 % of the identified
prescriptions were inappropriate when the CG equation
was used to estimate renal function; one-third of these
prescriptions had excessive doses given the patient’s renal
function and two-thirds were contraindicated. When the
CKD-EPI equation was used, the prevalence of inappro-
priate prescriptions was between 5 and 6 %. These preva-
lence figures differ from those reported in previous studies
of drug prescriptions that were inappropriate given
impaired renal function. In one study of patients aged
C70 years, 42.2 % of identified prescriptions had doses
exceeding current guidelines [21]. Another study found
13 % of prescriptions to be potentially inappropriate [18],
similar to our results. While the chosen renal function
estimation method might have affected the end result, we
also found that the CKD-EPI equation overestimates and
the CG equation underestimates renal function, which may
explain the differences in prevalence seen in the present
study [13, 15, 16]. Differences in the reported prevalence
of inappropriate prescriptions may also be because pre-
scribers and researchers use different prescribing or dosage
guidelines [4, 6, 8, 18–21]. For example, recommendations
on dosage limits for metformin differ between guidelines
[23, 26, 32]. In the present study, the majority of con-
traindicated prescriptions were for metformin, probably
because it is commonly prescribed and considered con-
traindicated for patients with an eGFR\ 60 ml/min,
according to the GDH [23]. Other guidelines continue to
recommend low-dose metformin in patients with
eGFRs[ 30 ml/min, which would alter the prevalence of
Table 4 Comparison between
patients with an eGFRCG[60








Simple OR Multiple OR
Sex
Men 71 (48.0) 87 (31.1) Reference









Living at home 105 (70.9) 199 (71.1) Reference




MMSE (0–30) 20.2 ± 5.1 19.6 ± 4.3 0.970
(0.900–1.046)
Data are presented as n (%) or mean ± standard deviation or odds ratio (95 % confidence interval). The
multiple analysis includes sex, age and living situation. MMSE is not included in the model because of the
small number of values obtained (n = 155), and the lack of a significant difference between the groups
eGFRCG estimated glomerular filtration rate using Cockcroft–Gault equation, MMSE Mini-Mental State
Examination, OR odds ratio
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Table 5 Renally cleared medications, together with dose recommendations, and frequency, n (%), of total and inappropriate prescriptions for
each identified drug [23]








Acamprosate 1 (0.2) – – –
CLcr\ 30 ml/min: contraindicated
Acetylsalicylic acid 152 (27.8) – – –
CLcr\ 10 ml/min: contraindicated
Alendronate 15 (2.7) – 2 (6.1) 2 (4.0)
CLcr\ 35 ml/min: contraindicated
Alfuzosin 20 (3.7) – 1 (3.0) 1 (2.0)
CLcr\ 30 ml/min: contraindicated
Allopurinol 21 (3.8) 8 (47.1) – 8 (16.0)
CLcr[ 140 ml/min: 400 mg/day
CLcr 121–140 ml/min: 350 mg/day
CLcr 101–120 ml/min: 300 mg/day
CLcr 81–100 ml/min: 250 mg/day
CLcr 61–80 ml/min: 200 mg/day
CLcr 41–60 ml/min: 150 mg/day
CLcr 21–40 ml/min: 100 mg/day
CLcr 11–20 ml/min: 100 mg every 2nd day
CLcr B 10 ml/min: 100 mg every 3rd day
Amiloride 5 (0.9) – – –
CLcr 10–50 ml/min: 20 mg/day
CLcr\ 10 ml/min: contraindicated
Amoxicillin 7 (1.3) 1 (5.9) – 1 (2.0)
CLcr 10–30 ml/min: 1000 mg/day
CLcr\ 10 ml/min: 500 mg/day
Ampicillin 1 (0.2) 1 (5.9) – 1 (2.0)
CLcr C 10 ml/min: 2000 mg/day
CLcr\ 10 ml/min: 1000 mg/day
Atenolol 10 (1.8) – – –
CLcr 15–35 ml/min: 50 mg/day
CLcr\ 15 ml/min: 50 mg every 2nd day
Azathioprine 2 (0.4) – – –
CLcr 10–50 ml/min: 75 % of 3 mg/kg/day
CLcr\ 10 ml/min: 50 % of 3 mg/kg/day
Bendroflumethiazide 19 (3.5) – 1 (3.0) 1 (2.0)
CLcr\ 30 ml/min: contraindicated
Cefadroxil 1 (0.2) – – –
CLcr 10–25 ml/min: 1000 mg/day
CLcr\ 10 ml/min: 1000 mg every 36th h
Cefotaxime 9 (1.6) 1 (5.9) – 1 (2.0)
CLcr 10–30 ml/min: 2000 mg/day
CLcr\ 10 ml/min: 2000 mg every 2nd day
Cetirizine 2 (0.4) 1 (5.9) – 1 (2.0)
CLcr 11–31 ml/min: 5 mg/day
CLcr\ 11 ml/min: contraindicated
Ciprofloxacin 4 (0.7) 1 (5.9) – 1 (2.0)
CLcr 30–50 ml/min: 1000 mg/day
CLcr 5–29 ml/min: 500 mg every 18th h
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Table 5 continued








Codeine 5 (0.9) – – –
CLcr 10–50 ml/min: ER 450 mg/day, IR 360 mg/day
CLcr\ 10 ml/min: ER 300 mg/day, IR 240 mg/day
Dabigatran 2 (0.4) – – –
CLcr\ 30 ml/min: contraindicated
Diclofenac 1 (0.2) – – –
CLcr\ 30 ml/min: contraindicated
Dihydroergotamine 2 (0.4) – – –
CLcr B 29 ml/min: contraindicated
Fesoterodine 1 (0.2) – – –
CLcr\ 30 ml/min: 4 mg/day
Fluconazole 2 (0.4) – – –
CLcr\ 50 ml/min: 400 mg/day
Fondaparinux 2 (0.4) – – –
CLcr\ 30 ml/min: contraindicated
Gabapentin 12 (2.2) – – –
CLcr C 60 ml/min: 3600 mg/day
CLcr 30–59 ml/min: 1400 mg/day
CLcr 16–29 ml/min: 700 mg/day
CLcr 15 ml/min: 300 mg/day
CLcr\ 15 ml/min: reduce daily dose (from 300 mg) in
proportion to CLcr
Galantamine 28 (5.1) 1 (5.9) – 1 (2.0)
CLcr 10–59 ml/min: 16 mg/day
CLcr\ 9 ml/min: contraindicated
Glibenclamide 8 (1.5) – 2 (6.0) 2 (4.0)
CLcr\ 50 ml/min: contraindicated
Glipizide 7 (1.3) – – –
CLcr\ 10 ml/min: contraindicated
Hydralazine 1 (0.2) – – –
CLcr 10–50 ml/min: 225 mg/day
Hydrochlorothiazide 17 (3.1) – 2 (6.1) 2 (4.0)
CLcr\ 30 ml/min: contraindicated
Ibuprofen 1 (0.2) – – –
CLcr\ 30 ml/min: contraindicated
Ketoprofen 2 (0.4) 1 (5.9) – 1 (2.0)
CLcr 25–89 ml/min: 150 mg/day
CLcr\ 25 ml/min: 100 mg/day
Levetiracetam 2 (0.4) – – –
CLcr[ 80 ml/min: 3000 mg/day
CLcr 50–80 ml/min: 2000 mg/day
CLcr 30–49 ml/min: 1500 mg/day
CLcr\ 30 ml/min: 1000 mg/day
Lithium 2 (0.4) – – –
CLcr 10–50 ml/min: 1800 mg/day
CLcr\ 10 ml/min: 1200 mg/day
Memantine 25 (4.6) 2 (11.8) – 2 (4.0)
CLcr 5–29 ml/min: 10 mg/day
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Table 5 continued








Methenamine 1 (0.2) – – –
CLcr\ 50 ml/min: contraindicated
Metformin 34 (6.2) – 12 (36.4) 12 (24.0)
CLcr\ 60 ml/min: contraindicated
Methotrexate 4 (0.7) – – –
CLcr\ 10 ml/min: contraindicated
Metoclopramide 3 (0.5) – – –
CLcr\ 40 ml/min: 30 mg/day
Mirabegron 3 (0.5) – – –
CLcr\ 15 ml/min: contraindicated
Morphine 40 (7.3) – 5 (15.2) 5 (10.0)
CLcr\ 30 ml/min: contraindicated
Naproxen 1 (0.2) – – –
CLcr\ 30 ml/min: contraindicated
Nitrofurantoin 5 (0.9) – 3 (9.1) 3 (6.0)
CLcr\ 60 ml/min: contraindicated
Norfloxacin 1 (0.2) – – –
CLcr B 30 ml/min: 400 mg/day
Piperacillin/tazobactam 1 (0.2) – – –
CLcr 20–40 ml/min: 8000/1000 mg/day
CLcr\ 20 ml/min: 6000/750 mg/day
Pramipexole 3 (0.5) – – –
ER formulations:
CLcr 30–50 ml/min: 2.25 mg/day
CLcr\ 30 ml/min: contraindicated
IR formulations:
CLcr 30–50 ml/min: 2.25 mg/day
CLcr 15–29 ml/min: 1.5 mg/day
CLcr\ 15 ml/min: contraindicated
Pregabalin 5 (0.9) – – –
CLcr C 60 ml/min: 600 mg/day
CLcr 30–59 ml/min: 300 mg/day
CLcr 15–29 ml/min: 150 mg/day
CLcr\ 15 ml/min: 75 mg/day
Raloxifene 1 (0.2) – 1 (3.0) 1 (2.0)
CLcr\ 59 ml/min: contraindicated
Ranitidine 1 (0.2) – – –
CLcr\ 50 ml/min: 150 mg/day
Risedronate 2 (0.4) – – –
CLcr\ 30 ml/min: contraindicated
Rosuvastatin 1 (0.2) – – –
CLcr\ 30 ml/min: 10 mg/day
Saxagliptin 1 (0.2) – – –
CLcr B 50 ml/min: 2.5 mg/day
Solifenacin 6 (1.1) – – –
CLcr\ 30 ml/min: 5 mg/day
Spironolactone 27 (4.9) – 3 (9.1) 3 (6.0)
CLcr\ 30 ml/min: contraindicated
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inappropriate prescription of this drug [26]. When met-
formin was excluded from the analysis, the prevalence of
inappropriate prescription was 7.4 %. Metformin is con-
sidered the first-line treatment for type 2 diabetes mellitus,
and monitoring of renal function is essential to avoid lactic
acidosis in patients receiving this drug [26, 32]. In addition
to metformin and allopurinol, we also documented more
than one inappropriate prescription each for alendronate,
glibenclamide, hydrochlorothiazide, memantine, morphine,
nitrofurantoin and spironolactone. In other studies, the
most frequently inappropriately prescribed drugs were non-
steroidal anti-inflammatory drugs, atenolol, gabapentin,
glyburide, ranitidine and nitrofurantoin [6, 8]. Gliben-
clamide has been associated with an increased risk of
hypoglycaemia compared with other sulfonylureas, and
other drugs in this class should be used for patients with
impaired renal function [23, 32]. Nitrofurantoin is con-
traindicated because impaired renal function decreases its
efficacy [23]. In general, patients with dementia or cogni-
tive impairment are especially vulnerable to ADRs, and it
Table 5 continued








Sulfamethoxazole/trimethoprim 1 (0.2) – – –
CLcr 15–30 ml/min: 1600/320 mg/day
CLcr\ 15 ml/min: contraindicated
Tolterodine 4 (0.7) – – –
CLcr 10–30 ml/min: 2 mg/day
Tramadol 4 (0.7) – 1 (3.0) 1 (2.0)
CLcr\ 30 ml/min: ER contraindicated, IR 200 mg/day
Trimethoprim 1 (0.2) – – –
CLcr 15–30 ml/min: 100 mg every 18th h
CLcr\ 15 ml/min: 100 mg/day
Venlafaxine 5 (0.9) – – –
CLcr 10–70 ml/min: 168.75 mg
Zoledronic acid 3 (0.5) – – –
CLcr\ 30 ml/min: contraindicated
Total, n (row %) 547 (100) 17 (3.1) 33 (6.0) 50a (9.1)
Data are presented as n (%)
CLcr creatinine clearance, ER extended release, GDH Geriatric Dosage Handbook, IR immediate release
a The number of inappropriate prescriptions shown in this table is not equal to the number of patients having identified inappropriate
prescriptions
Table 6 Comparison between those with correct versus inappropriate prescriptions among patients being prescribed a renally cleared
medication
Patient characteristics Correct prescriptions (n = 282) Inappropriate prescriptions (n = 44) Simple OR Multiple OR
Sex
Men 113 (40.1) 17 (38.6) Reference
Women 169 (59.9) 27 (61.4) 1.062 (0.553–2.038) 0.933 (0.477–1.826)
Age (years) 82.7 ± 6.5 84.8 ± 6.6 1.051 (0.999–1.105) 1.044 (0.991–1.100)
Living situation
Living at home 206 (73.0) 25 (56.8) Reference
Nursing home 76 (27.0) 19 (43.2) 2.060 (1.073–3.954) 1.889 (0.974–3.663)
MMSE (0–30) 19.5 ± 4.4 20.8 ± 4.0 1.074 (0.955–1.206)
Data are presented as n (%), mean ± standard deviation or OR (95 % confidence interval). The multiple analysis includes sex, age and living
situation. MMSE is not included in the model because of the small number of values obtained (n = 122), and the lack of a significant difference
between the groups
MMSE Mini-Mental State Examination, OR odds ratio
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is essential to avoid adverse reactions [33]. Hypoglycaemia
as an adverse reaction to glibenclamide or worsening
symptoms of urinary infection due to decreased nitrofu-
rantoin efficacy may have particularly harmful conse-
quences in this group. Older people with dementia are, on
average, prescribed more medicines than older people
without dementia [34]. This means it is even more
important and urgent to evaluate prescriptions of renally
excreted drugs to ensure that the correct doses are used and
further ADRs are avoided.
In this study, multiple logistic regression analysis
showed that age, sex and living in a nursing home were not
significantly associated with the record of one or more
potentially inappropriate prescription. In contrast, other
studies have found that inappropriate prescription in rela-
tion to renal function is more common in older people and
among those living in nursing homes [6, 22]. Our uni-
variate model showed that living situation was associated
with inappropriate prescription, but this association was not
significant in the multivariable model. People who live in
nursing homes may be older and have more concomitant
diseases that affect renal function than older people living
at home.
Some limitations of the present study should be
recognised. No baseline data about serum creatinine
were collected, nor were changes in values followed-up
during hospitalization. Therefore, we could not deter-
mine whether patients’ GFRs were stable because we
analysed only one serum creatinine level measurement
per patient [12]. Also, no other markers of kidney
damage were collected. Only one patient was admitted to
the acute internal medicine ward because of acute kidney
injury (AKI), but more people could possibly have suf-
fered from AKI even if the admission was classified
otherwise. Serum creatinine level was recorded on the
date of randomisation, which may have differed slightly
from the date of hospital admission—from which the
medication prescription data were taken. Actual body
weight was also used for all patients, regardless of body
composition, which may have affected eGFR values for
patients with unusual muscle mass. Pro re nata drugs
were not included in the analysis, which may have led to
underestimation of the prevalence of inappropriate pre-
scription; for example, pro re nata doses of morphine are
often prescribed. Dosage guidelines may differ between
different dosage references. The GDH was chosen
because of its international application and because it
specifically addresses recommended doses for older
people. However, the ranges for renal function were
quite narrow for some of the drug dosage guidelines,
which may have led to significant confounding in the
present study. The cross-sectional design of the study,
which involved assessment of patients’ prescriptions at
the time of the medication record review, means we
cannot comment on the appropriateness of medications
when they were initially prescribed. Height data were
lacking for six patients, which affected the absolute
eGFR values calculated from the relative GFRs esti-
mated using the CKD-EPI equation. MMSE test results
were available for only 155 patients in the sample.
The study’s strengths include the examination of a well-
defined group of patients and the collection of data from
hospital settings and medical records, which are reliable
sources of information for cross-sectional studies [35]. Data
such as serum creatinine level, weight and prescribed
medications were current. The CG equation was used to
estimate renal function for the purpose of estimating dosa-
ges in a medical care setting at the time the study was
conducted [2]. However, only serum creatinine was reported
in the medical records and prescribers then had to calculate
the eGFR themselves. Subsequent to completion of the
study, the CKD-EPI equation has become the current stan-
dard method used to calculate the eGFR in medical records.
The results thus provide a representative picture of clinical
reality at the time of the study [6, 17, 23, 25].
5 Conclusion
Impaired renal function is common and inappropriate
prescription is prevalent among old people with cognitive
impairment in northern Sweden. When prescribing medi-
cations, continuous consideration of renal function is
important to avoid ADRs among older people with
dementia or cognitive impairment.
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